Related Experiment Video
Updated: Sep 29, 2026
Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection
Published on: September 19, 2025
Dornase alfa in early cystic fibrosis lung disease
1Department of Respiratory Medicine, Royal Children's Hospital, Parkville, Australia.
Insights
Early intervention with dornase alfa in cystic fibrosis (CF) patients significantly reduces pulmonary exacerbations and improves lung function. This treatment is beneficial even in young patients with nearly normal lung function, supporting early therapeutic strategies.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Genetics
Background:
- Cystic Fibrosis (CF) lung disease is characterized by increased sputum viscosity due to leukocyte DNA release.
- This leads to chronic infection, inflammation, and progressive lung damage, even in early childhood.
- Early architectural lung damage is detectable in CF patients with normal pulmonary function tests.
Purpose of the Study:
- To evaluate the long-term benefits of dornase alfa in young CF patients with mild lung function abnormalities.
- To assess the efficacy of dornase alfa in reducing pulmonary exacerbations and improving lung function in this population.
Main Methods:
- The Pulmozyme Early Intervention Trial (PEIT) studied CF patients with near-normal lung function over a 2-year period.
- Dornase alfa was administered to assess its impact on pulmonary exacerbations and lung function parameters.
- Pulmonary function tests (PFTs) including FEF(25-75), MEF, and FEV(1) were monitored.
Main Results:
- Dornase alfa reduced the risk of pulmonary exacerbations requiring intravenous antibiotic treatment by 34%.
- Significant improvements were observed in forced expiratory flow at 25-75% (FEF(25-75)), mid-expiratory flow (MEF), and forced expired volume in 1 second (FEV(1)).
- A post hoc analysis indicated consistent reduction in exacerbations, though PFT changes varied with initial impairment.
Conclusions:
- Early intervention with dornase alfa provides significant benefits for CF patients, including reduced exacerbations and improved lung function.
- These findings support the use of dornase alfa early in the course of CF lung disease.
- Consistent reduction in exacerbations suggests dornase alfa is a valuable therapeutic option for CF management.
Abstract:
Leukocytes that infiltrate cystic fibrosis (CF) sputum as a result of infection have long been known to liberate large amounts of DNA, which increases sputum viscosity and promotes the cycle of chronic lung infection and inflammation that ultimately leads to respiratory failure and death. It was only recently recognized that this vicious cycle begins in infancy, and that architectural damage to CF lungs is detectable even in children with normal pulmonary function tests. Dornase alfa cleaves DNA and improves sputum viscosity in CF. Although its efficacy in reducing the risk of acute infectious exacerbations and improving pulmonary function has been recognized for a decade, there is growing interest in its potential for long-term benefit in young patients with mild lung function abnormalities. The Pulmozyme Early Intervention Trial (PEIT) study demonstrated that dornase alfa reduces the risk of pulmonary exacerbations requiring i.v. antibiotic treatment by 34% and improves forced expiratory flow at 25-75% of forced vital capacity (FEF(25-75)), mid-expiratory flow at 50% of forced vital capacity (MEF), and forced expired volume in 1 sec (FEV(1)) over a 2-year period in CF patients with almost normal lung function. A post hoc subgroup analysis suggests that the magnitude of pulmonary function test (PFT) changes may vary, depending on the initial degree of lung function impairment, but that the reduction in exacerbations appears to be a consistent benefit. These results support the current view that CF patients benefit from intervention early in the course of their lung disease.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
01:05Breathing